Soligenix, Inc. (SNGX)

NASDAQ: SNGX · IEX Real-Time Price · USD
0.460
+0.008 (1.79%)
At close: Feb 3, 2023, 4:00 PM
0.470
+0.010 (2.15%)
After-hours: Feb 3, 2023, 6:57 PM EST
1.79%
Market Cap 19.94M
Revenue (ttm) 858,496
Net Income (ttm) -14.75M
Shares Out 43.34M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 173,985
Open 0.457
Previous Close 0.452
Day's Range 0.432 - 0.480
52-Week Range 0.380 - 1.000
Beta 1.75
Analysts Buy
Price Target 4.21 (+815.02%)
Earnings Date Mar 27, 2023

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflamm... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 1987
Employees 13
Stock Exchange NASDAQ
Ticker Symbol SNGX
Full Company Profile

Financial Performance

In 2021, Soligenix's revenue was $824,268, a decrease of -65.07% compared to the previous year's $2.36 million. Losses were -$12.55 million, -29.04% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SNGX stock is "Buy." The 12-month stock price forecast is $4.21, which is an increase of 815.02% from the latest price.

Price Target
$4.21
(815.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Soligenix Invited to Present at the Virtual Investor Summit Event

Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the C...

2 weeks ago - PRNewsWire

Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

PRINCETON, N.J. , Dec. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

1 month ago - PRNewsWire

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge

RiVax ® - Vaccinated NHP survival was statistically significantly correlated with an epitope-specific serum assay ("EPICC") prior to challenge Correlates of protection are essential to support approva...

1 month ago - PRNewsWire

Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis

Study HPN-PSR-01 opens patient enrollment PRINCETON, N.J. , Dec. 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on d...

1 month ago - PRNewsWire

7 Stocks to Add to Your 10x Watchlist

There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfol...

1 month ago - InvestorPlace

Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma

PRINCETON, N.J. , Dec. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

1 month ago - PRNewsWire

Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

PRINCETON, N.J. , Nov. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

2 months ago - PRNewsWire

Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference

Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summit l...

3 months ago - Newsfile Corp

Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results

PRINCETON, N.J. , Nov. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

3 months ago - PRNewsWire

Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses

Emerging infectious diseases where n o protective vaccines are currently available SuVax™ targets Sudan ebolavirus, origin of a current disease outbreak in Uganda PRINCETON, N.J. , Oct. 27, 2022 /PRNe...

3 months ago - PRNewsWire

Soligenix Announces Formation of Psoriasis Medical Advisory Board

Phase 2a clinical study in mild-to-moderate psoriasis initiating  in December 2022 PRINCETON, N.J. , Oct. 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-sta...

3 months ago - PRNewsWire

Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting

Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern Time Soligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to vote by 11:59 p.m.

3 months ago - PRNewsWire

Soligenix Enters Q4 With Multiple Catalysts in Play

New York, New York--(Newsfile Corp. - October 13, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentia...

4 months ago - Newsfile Corp

Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting

- Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59...

4 months ago - PRNewsWire

FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL

New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the ...

5 months ago - Newsfile Corp

Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PRINCETON, N.J. , Sept. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

5 months ago - PRNewsWire

U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Grant supports study of expanded HyBryte™ treatment, including in the Home Use Setting PRINCETON, N.J. , Sept. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late...

5 months ago - PRNewsWire

Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results

PRINCETON, N.J. , Aug. 12, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

6 months ago - PRNewsWire

Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

PRINCETON, N.J. , July 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

6 months ago - PRNewsWire

Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients

HyBryte(TM) NDA Anticipated in H2 2022New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX), has completed the larg...

6 months ago - Newsfile Corp

Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen

SERB Pharmaceuticals pursuing therapeutic treatment  against ricin poisoning using Soligenix ricin antigen PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or ...

6 months ago - PRNewsWire

Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study

Soligenix Inc (NASDAQ: SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) had been published in the Journal of the Ame...

7 months ago - Benzinga

HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Published findings demonstrate that HyBryte™ treatment statistically significantly reduced CTCL lesion size HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON,...

7 months ago - PRNewsWire

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis

Enrollment on Track to Begin in 4th   Quarter of 2022 PRINCETON, N.J. , June 28, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company ...

7 months ago - PRNewsWire

Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine

Bivalent vaccine provides 100% protection in non-human primates against both Sudan ebolavirus and Marburg marburgvirus Only subunit (protein) vaccine platform shown to protect against potentially leth...

8 months ago - PRNewsWire